Stuart Schreiber, Ph.D.
Ramnik Xavier, MD, Ph.D.
Stuart Schreiber is co-Founder of the Broad Institute, Howard Hughes Medical Institute Investigator, Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University, and has been a member of the National Academy of Sciences since 1995.
His lab integrates chemical biology and human biology to advance the science of therapeutics. He is known for having developed systematic ways to explore biology, especially disease biology, using small molecules and for his role in the development of the field of chemical biology. Key advances include the discoveries of mTOR, histone deacetylases and evidence that chromatin marks regulate gene expression, and small molecules that promote protein–protein interactions. His research has been acknowledged through awards including most recently the Wolf Prize in Chemistry. His approach to therapeutics discovery guided the development of many biotechnology companies including Vertex Pharmaceuticals and Ariad Pharmaceuticals.
Ramnik Xavier is Chief of Gastroenterology at Massachusetts General Hospital (MGH), Kurt Isselbacher Professor of Medicine at Harvard Medical School, institute member of the Broad Institute of MIT and Harvard, and the director of MGH’s Center for the Study of Inflammatory Bowel Disease (IBD). As a clinical gastroenterologist and molecular biologist, he studies the specific molecular mechanisms involved in innate and adaptive immunity as well as the genetic variants associated with Crohn’s disease, ulcerative colitis, and autoimmunity. His laboratory uses genetic, structural, computational, and animal models, as well as clinical research to define the mechanisms controlling inflammation and immunity in vivo.
Charlie joined Editas Medicine as Chief Scientific Officer in August 2016. He brings more than 25 years of life sciences industry and academic leadership experience, most recently serving as vice president of genetically defined diseases and genomics at Bristol-Myers Squibb (BMS). Over his career, Charlie has led discovery programs that advanced investigational medicines into clinical development in a wide range of therapeutic areas, including neurodegeneration, pain, psychiatry, oncology and inflammation. Prior to his position as vice president of genetically defined diseases and genomics, he held multiple scientific leadership roles in neuroscience biology at BMS. Previously, he held positions at Incyte Corporation and DuPont Pharmaceuticals and was an assistant professor of biochemistry at Vanderbilt University. Charlie received a Bachelor of Science in Chemical Engineering and a Ph.D. in biology from the Massachusetts Institute of Technology (MIT). He was a postdoctoral fellow in the laboratory of Professor Robert Weinberg at the Whitehead Institute for Biomedical Research at MIT.